Diaminodiphenylsulfone (dapsone) has long been used as a first-line drug worldwide for the treatment of leprosy. Diagnosis for dapsone resistance of Mycobacterium leprae by DNA tests would be of great clinical value, but the relationship between the nucleotide substitutions and susceptibility to dapsone must be clarified before use. In this study, we constructed recombinant strains of cultivable Mycobacterium smegmatis carrying the M. leprae folP1 gene with or without a point mutation, disrupting their own folP gene on the chromosome. Dapsone susceptibilities of the recombinant bacteria were measured to examine influence of the mutations. Dapsone MICs for most of the strains with mutations at codon 53 or 55 of M. leprae folP1 were 2 to 16 times as high as the MIC for the strain with the wild-type folP1 sequence, but mutations that changed Thr to Ser at codon 53 showed somewhat lower MIC values than the wild-type sequence. Strains with mutations at codon 48 or 54 showed levels of susceptibility to dapsone comparable to the susceptibility of the strain with the wild-type sequence. This study confirmed that point mutations at codon 53 or 55 of the M. leprae folP1 gene result in dapsone resistance.
The massive use of dapsone for treatment of leprosy led to the isolation of resistant strains of Mycobacterium leprae as early as 1964 (11) , only a few years after discovery of the drug. Dapsone is structurally related to the sulfonamides. The mechanism of dapsone resistance in M. leprae is thought to be associated with dihydropteroate synthase (DHPS) in a manner similar to the mechanism of resistance to sulfonamides developed in other bacteria. The sulfonamides are structural analogs of p-aminobenzoate (PABA) and act as antimetabolites by competing with PABA for the active site of DHPS (4) . DHPS catalyzes the reaction between dihydropteridine pyrophosphate and PABA as a part of the biosynthetic pathway leading to tetrahydrofolate (5, 12) , which acts as a cofactor in the biosynthesis of purines, pyrimidines, and amino acids. Resistance to the sulfonamides has been shown to be mediated by mutations of the chromosomal folP gene encoding DHPS (7, 14, 15) . Point mutations in the folP1 gene have been identified in dapsone-resistant strains of M. leprae (9, 10, 16) . Because M. leprae cannot be cultivated on any artificial medium and requires 13 days to double in experimentally infected mice, DNA diagnoses to detect dapsone-resistant bacteria would be highly useful. However, not all nucleotide substitutions in the folP1 gene give rise to drug resistance. Therefore, the relationship between drug susceptibility and each nucleotide substitution observed in clinical isolates requires clarification. Dapsoneresistant M. leprae isolates have shown mutation at codon 53 or 55 in the folP1 gene (6, 10, 16) . Mutation at codon 48 has also been detected in our clinical specimens (unpublished data). Williams et al. have analyzed two types of mutations at codons 53 and 55 of the M. leprae folP1 gene using a folP-deficient Escherichia coli (16) . However, their analysis is as yet insufficient for direct application as molecular diagnosis for dapsone resistance.
In this study, site-directed mutagenesis techniques were used to alter the wild-type M. leprae folP1 gene at codons shown to be mutated in clinical isolates for testing the effects of these mutations on dapsone susceptibility in a folP-disrupted Mycobacterium smegmatis host.
MATERIALS AND METHODS
Bacterial strains and plasmids. Bacterial strains and plasmids used in this study are listed in Table 1 . E. coli DH5␣ cells were grown in Luria-Bertani (LB) medium. M. smegmatis mc 2 155 and its transformants were grown in Middlebrook 7H9 medium (Difco, Detroit, MI) supplemented with 0.5% bovine serum albumin (fraction V), 0.2% glucose, 0.085% NaCl, 0.2% glycerol, and 0.1% Tween 80.
Site-directed mutagenesis. The wild-type M. leprae folP1 gene was amplified by PCR from M. leprae Thai-53 and cloned into pMV261. Site-directed mutagenesis was performed using PCR with KOD DNA polymerase (Toyobo, Osaka, Japan) and the primers listed in Table 2 . PCR products were purified and phosphorylated with T4 kinase and ATP and then ligated to become circular. The ligation mixture was used to transform E. coli DH5␣, and kanamycin-resistant colonies were isolated. Plasmids were extracted from the transformants, and the mutated sequences were confirmed by sequencing. Mutations introduced in the M. leprae folP1 gene are shown in Fig. 1A .
Disruption of the folP gene on the M. smegmatis chromosome. M. smegmatis mc 2 155 cells were transformed with plasmids carrying the M. leprae folP1 with or without a point mutation. Recombinants were selected on LB medium containing kanamycin. Allelic exchange mutants were constructed by the temperaturesensitive mycobacteriophage method (3). Using the M. smegmatis mc 2 155 genome sequence (accession number CP000480), the upstream and downstream flanking DNA sequences were used to generate a deletion mutation in the folP gene (MSMEG_6103). In order to disrupt the folP gene, DNA segments from 736 bp upstream through 286 bp downstream of the initiation codon of M. smegmatis folP and from 198 bp upstream through 832 bp downstream of the termination codon were cloned directionally into the cosmid vector pYUB854, which contains a res-hyg-res cassette and a cos sequence for lambda phage assembly. Plasmids thus produced were digested with PacI and ligated to the PH101 genomic DNA excised from the phasmid phAE87 by PacI digestion. The ligated DNA was packaged using GigaPackIII Gold Packaging Extract (Stratagene, La Jolla, CA), and the resultant mixture was used for transduction of E. coli STBL2 (Life Technologies, Carlsbad, CA) to yield cosmid DNA. After E.
coli was transduced and the transductants were plated on hygromycin-containing medium, phasmid DNA was prepared from the pooled antibiotic-resistant transductants and electroporated into M. smegmatis mc 2 155. Bacterial cells were incubated at 30°C to produce the recombinant phage. The M. smegmatis transformant carrying the M. leprae folP1 gene was infected by the produced temperature-sensitive phage at 37°C for allelic exchange, and kanamycin-and hygromycin-resistant colonies were isolated. Two colonies for each point mutation were subjected to subsequent tests.
Dapsone susceptibility testing. The MIC values for M. smegmatis recombinant clones were determined by culture on Middlebrook 7H10 agar plates containing 2-fold serial dilutions of dapsone (0.25 to 64 g/ml). The MIC value for each strain was defined as the lowest concentration of dapsone needed to inhibit bacterial growth.
RESULTS
Construction of recombinant M. smegmatis strains. We prepared plasmids with point mutations in the M. leprae folP1 gene. Each plasmid has 1 of 21 single point mutations at codon 48, 53, 54, or 55 (Fig. 1A) . The first or second nucleotide at each codon was replaced by another nucleotide to change the amino acid residue. Mutated sequences were confirmed by sequencing. Plasmids carrying the M. leprae folP1 with or without a point mutation were individually introduced into M. smegmatis. The M. smegmatis transformants were subjected to allelic exchange to disrupt the folP gene on their own chromosome (Fig. 1B) . PCR analysis confirmed that the folP sequences in the recombinant strains were replaced by hygromycin resistance gene sequences (Fig. 2) . Isolation of a folP-disrupted M. smegmatis strain carrying the M. leprae folP1 with mutation 48-4 (mutation 4 at codon 48) was unsuccessful. All the strains except for the strains with mutation 48-5 or 53-4 showed comparable growth rates. The strains with mutation 48-5 or 53-4 grew a little more slowly than the strain with the wild-type sequence. These two mutations may reduce DHPS activity.
Dapsone susceptibility. Dapsone susceptibilities of the recombinant M. smegmatis strains were tested. As shown in Fig.  3 , the MIC of dapsone for recombinant M. smegmatis carrying the wild-type M. leprae folP1 gene was 0.5 g/ml. MIC values for most of the strains with mutations at codon 53 or 55 were 2 to 16 times as high as the MIC for the strain with the wild-type sequence. Interestingly, two strains with alterations 
DISCUSSION
We first attempted using E. coli C600 ⌬folP::Km r transformants to determine the MIC of dapsone, but susceptibility of the recombinant E. coli strains to dapsone was not stable even in Mueller-Hinton medium. Subsequently, we tried to isolate a folP-deficient M. smegmatis strain by allelic exchange, given the closer association of M. smegmatis to M. leprae than E. coli. The selection held great promise as total-sequence comparison of M. leprae DHPS with M. smegmatis DHPS indicated 83% identity, whereas the identity between M. leprae DHPS and E. coli DHPS is only 41%, indicating the higher potential of M. smegmatis as a host for measuring MIC values of dapsone for M. leprae DHPS. However, isolation of folP-deficient M. smegmatis was unsuccessful. In E. coli, DHPS is not essential for bacterial growth when the cells are cultured with thymidine (7), but DHPS activity may be essential for the growth of M. smegmatis as it could not be replaced by any of the supplemented culture media tested. Hence, we then attempted to disrupt the folP gene on the M. smegmatis chromosome after introducing the M. leprae folP1 gene into the cell to compensate for DHPS activity.
Comparison of the DHPS structures of E. coli, Staphylococcus aureus, and Mycobacterium tuberculosis has suggested that Ser53 and Pro55 of the M. tuberculosis DHPS, which correspond to Thr53 and Pro55 in M. leprae, may be the major sites of interaction with PABA, dapsone, and sulfonamides (1, 2, 8) .
In the present study, all mutations that cause amino acid sub- stitutions at codon 55 resulted in dapsone resistance. Mutations at codon 53 also gave rise to dapsone resistance except for the T53S substitution, which resulted in less resistance to dapsone than the wild-type sequence (Fig. 3) . The results for mutation 53-1, 53-2, 55-5, and 55-6 are consistent with the mouse footpad dapsone susceptibility testing of the M. leprae clinical isolates (6, 10, 16) . Mutations at codon 48 or 54 showed comparable levels of susceptibility to dapsone as the wild-type sequence using dapsone susceptibility testing, but the MIC values for mutations 48-3, 48-5, 48-6, and 54-2 were slightly higher than the MIC for the wild-type sequence. Mutation 48-5 for V48A, which has been detected in our clinical samples (unpublished data), might give rise to low-level resistance to dapsone in M. leprae. This level of resistance should be very carefully examined by comparison with the results of footpad testing and clinical data. These data will help the molecular diagnosis of dapsone-resistant M. leprae with the goal of avoiding the wrong choice of drugs for chemotherapy. Although these results should always be initially confirmed by clinical susceptibility testing as well, we believe that the method established in this study should have great utility in further attempts to determine the mutations responsible for giving rise to the dapsone resistance of M. leprae. The advantage of this method lies in the ability to functionally replace an essential gene of fast-growing mycobacteria with the M. leprae counterpart. The method may also be applicable to analysis of the rifampin resistance and quinolone resistance of M. leprae.
